VR Logo

VectivBio Holding AG (VECT) download report


Healthcare | Biotechnology & Pharma Research

VectivBio Holding AG (VECT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions.

IPO Date: 08-Apr-2021

Founder, CEO & Director: Dr. Luca Santarelli M.D.

Chief Financial Officer: Ms. Claudia D'Augusta Ph.D.

Listing: NASDAQ: VECT

Country: Switzerland

Headquarters: Basel,

Website: https://vectivbio.com

Key Facts

Market cap: $255.03 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-87.01 Mln

Cash: $102.71 Mln

Total Debt: $0.00 Mln

Insider's Holding: 8.37%

Liquidity: Low

52 Week range: $2.74 - 11.52

Shares outstanding: 35,973,300

Stock Performance

Time Period VectivBio Holding AG (VECT) S&P BSE Sensex S&P Small-Cap 600
YTD22.20-9.18-19.06
1 month-3.76-4.78-8.32
3 months27.39-9.66-13.96
1 Year-48.540.81-17.48
3 Years--10.335.97
5 Years--11.345.80
10 Years--11.749.80
As on 01-Jul-2022